Study of NGX-1998 for the Treatment of Postherpetic Neuralgia
Public ClinicalTrials.gov record NCT01228838. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Randomized, Double-Blind, Controlled Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Two Capsaicin Concentration Variations of NGX-1998 (10% or 20% w/w) in Subjects With Postherpetic Neuralgia (PHN)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the efficacy, safety and tolerability of NGX-1998 applied for 5 minutes for the treatment of postherpetic neuralgia (PHN).
Study identification
- NCT ID
- NCT01228838
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 183 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2010 (Type not available)
- Primary completion
- Sep 2011 (Actual)
- Completion
- Sep 2011 (Actual)
- Last update posted
- Sep 10, 2012
2010 – 2011
United States locations
- U.S. sites
- 35
- U.S. states
- 24
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NeurogesX Investigational Site | Huntsville | Alabama | — | — |
| NeurogesX Investigational Site | Tucson | Arizona | — | — |
| NeurogesX Investigational Site | Irvine | California | — | — |
| NeurogesX Investigational Site | La Jolla | California | — | — |
| NeurogesX Investigational Site | Napa | California | — | — |
| NeurogesX Investigational Site | San Francisco | California | — | — |
| NeurogesX Investigational Site | Santa Monica | California | — | — |
| NeurogesX Investigational Site | New Port Richey | Florida | — | — |
| NeurogesX Investigational Site | North Palm Beach | Florida | — | — |
| NeurogesX Investigational Site | Sarasota | Florida | — | — |
| NeurogesX Investigational Site | St. Petersburg | Florida | — | — |
| NeurogesX Investigational Site | Marietta | Georgia | — | — |
| NeurogesX Investigational Site | Boise | Idaho | — | — |
| NeurogesX Investigational Site | Bloomington | Illinois | — | — |
| NeurogesX Investigational Site | West Des Moines | Iowa | — | — |
| NeurogesX Investigational Site | Kansas City | Kansas | — | — |
| NeurogesX Investigational Site | Lexington | Kentucky | — | — |
| NeurogesX Investigational Site | Shreveport | Louisiana | — | — |
| NeurogesX Investigational Site | Hyannis | Massachusetts | — | — |
| NeurogesX Investigational Site | Ann Arbor | Michigan | — | — |
| NeurogesX Investigational Site | Minneapolis | Minnesota | — | — |
| NeurogesX Investigational Site | Hattiesburg | Mississippi | — | — |
| NeurogesX Investigational Site | Albany | New York | — | — |
| NeurogesX Investigational Site | Rochester | New York | — | — |
| NeurogesX Investigational Site | Hickory | North Carolina | — | — |
| NeurogesX Investigational Site | Winston-Salem | North Carolina | — | — |
| NeurogesX Investigational Site | Portland | Oregon | — | — |
| NeurogesX Investigational Site | Altoona | Pennsylvania | — | — |
| NeurogesX Investigational Site | San Antonio | Texas | — | — |
| NeurogesX Investigational Site | Webster | Texas | — | — |
| NeurogesX Investigational Site | Salt Lake City | Utah | — | — |
| NeurogesX Investigational Site | Richmond | Virginia | — | — |
| NeurogesX Investigational Site | Seattle | Washington | — | — |
| NeurogesX Investigational Site | Wenatchee | Washington | — | — |
| NeurogesX Investigational Site | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01228838, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2012 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01228838 live on ClinicalTrials.gov.